Homepage
Author:
BioVie, Inc.
Posted Date:
May 18, 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
BioVie, Inc.
May 18, 2026
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie, Inc.
April 27, 2026
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
BioVie, Inc.
April 14, 2026
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
BioVie, Inc.
March 12, 2026
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
BioVie, Inc.
February 23, 2026
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
BioVie, Inc.
February 12, 2026
